Marshall Fordyce, MD
Gilead Sciences
3
0
3
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (3)
Research Network
Collaboration Network
Research Areas & Affiliations
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Pablo Tebas, MD
University of Pennsylvania
Shared therapeutic areas:
Jamie Ostroff, PhD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
François Raffi, PHD
Hopital Hotel Dieu Nantes
Shared therapeutic areas:
Gilles Pichancourt
CH Henri Duffaut Avignon
Shared therapeutic areas:
Bruno Marchou, PHD
CHU Purpan (Toulouse)
Shared therapeutic areas:
Jean Luc Schmit
Hôpital Nord Amiens
Shared therapeutic areas:
André Cabié
CHU Fort de France
Shared therapeutic areas:
Antoine Chéret
CH TOURCOING
Shared therapeutic areas:
JP Viard, MD
Hotel Dieu Paris
Shared therapeutic areas:
Daniel Sereni, PHD
St Louis ¨Paris
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (3)
Showing 3 of 3 trials
Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
All 3 trials loaded